Search Videos and More
News
A Year of Advances in Genitourinary Cancer
Dana-Farber’s genitourinary cancer team is devoted to research that will advance patient care and improve patient’s lives. Recently, that research — all of it years in the making — has paid off with major achievements.
News
What is a Menin Inhibitor?
Menin, a protein located in the nucleus of various human cell types, often functions as a tumor suppressor by inhibiting excessive cell growth and division.
News
Dana-Farber Research News 02.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from January 1 through January 15.
News
Can Metastatic Breast Cancer Be Cured?
When Yvonne Fantaci discovered she had breast cancer at age 60, it had already spread to her lungs, liver, and elsewhere. Fantaci felt blindsided. She was otherwise completely healthy. She never expected such a shocking diagnosis.
News
Expanding Options for Patients with Ovarian Cancer
In 2021, a novel drug called belzutifan was approved by the U.S. Food and Drug Administration (FDA) to treat clear cell renal cell carcinoma, a form of kidney cancer.
News
Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence
A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment.
News
Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia
Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.
News
Dana-Farber Research News 01.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 through December 15.
News
Dana-Farber and Gustave Roussy Announce 2025 Transatlantic Exchange Scientific Program to Focus on Radioligand Therapy
Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Fourth Transatlantic Exchange in Oncology Conference topic will be “Radiopharmaceutical Therapy Meets Oncology.”
Video
Ann Lacasce, MD, MMSc discusses treatment in early stage high-risk cHL patients
Ann Lacasce MD, MMSc, of Dana-Farber Cancer Institute presented findings at #ASH24 suggesting treatment with brentuximab vedotin and nivolumab can reduce toxicities and may decrease the need for radiation in early stage high-risk cHL patients.
Video
Daniel DeAngelo, MD, PhD on a novel systemic mastocytosis (SM) drug
Daniel DeAngelo, MD, PhD, of Dana-Farber Cancer Institute, presented findings at #ASH24 on two abstracts regarding a novel systemic mastocytosis (SM) drug with high response rates & a tool that identifies SM subtypes with 90% accuracy.
Video
Colleen Kelly, MD discusses findings on RISE
At #ASH24, researcher, Colleen Kelly MD, presented findings on RISE, a Dana-Farber led program aiding low-income families of kids with cancer. Results show promise.